Amgen Inc.

Ngm Biopharmaceuticals, Inc.

Medarex Inc.

E. R. Squibb Sons, Inc.

Ucb Pharma, S.a.

Ucb S.a.

Wenyan Shen

Hugo Matern

Simon Mark Jackson

Chadwick Terence King

Randal Robert Ketchem

Christopher Mehlin

Teresa Arazas Carabeo

Derek Evan Piper

Nigel Pelham Clinton Walker

Bei Shan

Taruna Arora

Yu Chen

Betty Chan Li

Kalyani Mondal

Yan Wang

Haichun Huang

Darrin Anthony Lindhout

Hsieng Sen Lu

Steven Kiyoshi Yoshinaga

Raj Haldankar

Gerald Siu

Jie Tang

Gordon Ng

John A Latham

David Guenther Winkler

Kevin Graham

Christopher J Paszty

Ji Li

Thomas Charles Boone

Jeonghoon Sun

Martyn Kim Robinson

Zhonghao Liu

Francis Hall Martin

John Latham

Mingyue Zhou

Margrit Schwarz

David Park Meininger

Tom Boone

Alastair Lawson

Alistair James Henry

William Gleason Richards

Aaron George Winters

Andy Popplewell

Joyce Chi Yee Chan

Paul Kostenuik

Anja Leona Biere-Citron

Kelly Sue Warmington

Thomas M Dillon

Qiong Cao

Chen Zhou

Kelly Sue Hoffmann

Chadwick Terrence King

Amy Guo

Christopher John Vezina

Kelly Sue Hoffman

Marty Kim Robinson

Margit Schwarz

Margaret Speed Ricci

Jette Wypych

David Winkler

Christopher Paszty

Pavel Bondarenko

Alain Balland

Martin J Allen

The present disclosure provides binding proteins, such as antibodies or binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use such as in producing an antibody or binding fragment thereof. The present disclosure also provides vectors and cells comprising polynucleotides encoding antibodies or binding fragments thereof that bind beta klotho, including human beta klotho.

Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof

The present disclosure provides binding proteins, such as antibodies, that bind to a GDNF Family Receptor Alpha Like (GFRAL) protein, including human GFRAL protein, and methods of their use.

Binding proteins and methods of use thereof

A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.

Compositions and methods of use for treating metabolic disorders

The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use.

Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor

The present disclosure provides binding proteins, such as antibodies, and binding fragments thereof, that bind beta klotho, including human beta klotho, and exemplary specific sequences of their complementarity determining regions, variable regions, heavy chains, and light chains. The present disclosure also provides method of making the antibody or fragment thereof and methods of their use, including, in activating beta-klotho/FGF receptor complex, inducing FGF19-like and/or FGF21-like signaling, improving glucose and lipid metabolism, and treatment of nonalcoholic steatohepatitis.

Anti-human beta klotho antibody or binding fragment thereof and methods of their use

The present disclosure provides binding proteins, such as antibodies and binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use, including in the treatment of nonalcoholic steatohepatitis. The present disclosure also provides exemplary specific sequences of complementarity determining regions, variable regions, heavy chains, and light chains of the antibodies and/or binding fragments thereof.

Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof

Antibodies which bind human glucagon receptor

The present disclosure provides binding proteins, such as antibodies, that bind beta klotho, including human beta klotho, and methods of their use.

Beta klotho-binding proteins

Beta klotho-binding proteins and methods of use thereof

Beta-klotho binding proteins

This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.

Human anti-B7RP1 neutralizing antibodies

Growing community of inventors

Thousand Oaks, CA, United States of America

Wenyan Shen